Latest News and Press Releases

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at...

CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....

- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and...

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug...

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines...

CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that SYNB1934 was granted...

Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...